Overview

A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer

Status:
Recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of abiraterone acetate in Indian participants with metastatic, castration-resistant prostate cancer who have been prescribed abiraterone acetate as per locally approved prescribing information.
Details
Lead Sponsor:
Johnson & Johnson Private Limited
Treatments:
Abiraterone Acetate